JP2024537250A - インフルエンザワクチン - Google Patents

インフルエンザワクチン Download PDF

Info

Publication number
JP2024537250A
JP2024537250A JP2024521254A JP2024521254A JP2024537250A JP 2024537250 A JP2024537250 A JP 2024537250A JP 2024521254 A JP2024521254 A JP 2024521254A JP 2024521254 A JP2024521254 A JP 2024521254A JP 2024537250 A JP2024537250 A JP 2024537250A
Authority
JP
Japan
Prior art keywords
amino acid
seq
polypeptide
acid sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024521254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537250A5 (cg-RX-API-DMAC7.html
Inventor
ジョナサン ルーク ヒーニー,
スネハ ビシュワナス,
ジョージ カーネル,
デイビッド ウェルズ,
サイモン フロスト,
マッテオ フェラーリ,
ベネディクト アスバッハ,
ラルフ ヴァーグナー,
Original Assignee
ディオシンバックス リミテッド
ザ チャンセラー, マスターズ アンド スカラーズ オブ ザ ユニバーシティー オブ ケンブリッジ
ウニヴェルジテート レーゲンスブルク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2114328.4A external-priority patent/GB202114328D0/en
Priority claimed from GBGB2208070.9A external-priority patent/GB202208070D0/en
Priority claimed from GBGB2213958.8A external-priority patent/GB202213958D0/en
Application filed by ディオシンバックス リミテッド, ザ チャンセラー, マスターズ アンド スカラーズ オブ ザ ユニバーシティー オブ ケンブリッジ, ウニヴェルジテート レーゲンスブルク filed Critical ディオシンバックス リミテッド
Publication of JP2024537250A publication Critical patent/JP2024537250A/ja
Publication of JP2024537250A5 publication Critical patent/JP2024537250A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024521254A 2021-10-06 2022-10-06 インフルエンザワクチン Pending JP2024537250A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2114328.4 2021-10-06
GBGB2114328.4A GB202114328D0 (en) 2021-10-06 2021-10-06 Influenza vaccines
GBGB2208070.9A GB202208070D0 (en) 2022-05-31 2022-05-31 Influenza vaccines
GB2208070.9 2022-05-31
GB2213958.8 2022-09-23
GBGB2213958.8A GB202213958D0 (en) 2022-09-23 2022-09-23 Influenza vaccines
PCT/GB2022/052534 WO2023057766A1 (en) 2021-10-06 2022-10-06 Influenza vaccines

Publications (2)

Publication Number Publication Date
JP2024537250A true JP2024537250A (ja) 2024-10-10
JP2024537250A5 JP2024537250A5 (cg-RX-API-DMAC7.html) 2025-10-15

Family

ID=83692952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521254A Pending JP2024537250A (ja) 2021-10-06 2022-10-06 インフルエンザワクチン

Country Status (6)

Country Link
US (1) US20240408190A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412644A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024537250A (cg-RX-API-DMAC7.html)
AU (1) AU2022360009A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234653A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023057766A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004825D0 (en) * 2020-04-01 2020-05-13 Diosynvax Ltd Influenza vaccines
GB202315888D0 (en) * 2023-10-17 2023-11-29 Diosynvax Ltd Influenza vaccines
WO2026018213A1 (en) * 2024-07-18 2026-01-22 Vaxthera Sas A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
WO2026074282A1 (en) * 2024-10-01 2026-04-09 Diosynvax Ltd. Influenza vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083533A1 (es) * 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2013075266A1 (en) * 2011-11-23 2013-05-30 Vacdiagn Biotechnology Co., Ltd. Immune methods against influenza viruses and combinatorial vaccines thereof
CA2863949C (en) * 2012-02-13 2021-06-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
US12064478B2 (en) * 2018-09-21 2024-08-20 Nutech Ventures Methods of making and using universal centralized influenza vaccine genes

Also Published As

Publication number Publication date
CA3234653A1 (en) 2023-04-13
AU2022360009A1 (en) 2024-05-23
WO2023057766A1 (en) 2023-04-13
US20240408190A1 (en) 2024-12-12
EP4412644A1 (en) 2024-08-14

Similar Documents

Publication Publication Date Title
JP7655849B2 (ja) ヘマグルチニン(ha)タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
AU2017203189B2 (en) Expression systems
JP6294828B2 (ja) インフルエンザウイルスワクチンおよびその使用
US7981428B2 (en) Flu vaccines and methods of use thereof
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
US10729758B2 (en) Broadly reactive mosaic peptide for influenza vaccine
CN101484466A (zh) 针对流感病毒的抗病毒剂和疫苗
CN111526886A (zh) 多基因流感疫苗
CA3234653A1 (en) Influenza vaccines
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
JP2023522154A (ja) インフルエンザワクチン
JP2021511077A (ja) インフルエンザウイルスワクチン及びその使用
WO2021220246A1 (en) Recombinant sars-cov-2 polypeptides and uses
JP2022547107A (ja) インフルエンザウイルスワクチン及びその使用
CN113801206B (zh) 利用受体识别域诱导抗新冠病毒中和抗体的方法
JP2018052953A (ja) インフルエンザウイルスワクチンおよびその使用
EP4687969A1 (en) Coronavirus vaccines inducing broad immunity against variants
JP2026508394A (ja) コロナウイルスワクチン
CN107841513B (zh) 基于M2e表位的广谱型流感疫苗
US11723968B2 (en) Stabilized recombinant hantaviral spike proteins comprising mutations in Gc
CN118922204A (zh) 流感疫苗
HK40090677A (en) Influenza vaccines
WO2025083402A1 (en) Coronavirus vaccines
US20130243808A1 (en) Compositions and methods for vaccinating humans and animals against enveloped viruses
WO2025083412A2 (en) Influenza vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251006